Table 1.
Globally authorized COVID-19 vaccines.
| Manufacturer | Vaccine type | Dose(s) recommended | Efficacy | Safety and reactogenicity | Immunogenicity |
|---|---|---|---|---|---|
| Sinovac/CoronaVac | Inactivated | 2-dose | 50.38% | Safe | Well tolerated and induced humoral responses |
| Sinopharm (Beijing)/BBIBP-CorV | Inactivated | 2-dose | 73.9% | Safe | Immunogenic and induced robust humoral responses rapidly |
| Bharat Biotech/COVAXIN | Inactivated | 2-dose | 81.0% | Safe | Enhanced humoral and cell-mediated immune responses |
| Sinopharm (Wuhan)/Inactivated (Vero Cell) | Inactivated | 2-dose | 72.5% | Safe | Immunogenic; high neutralizing antibody response is seen after 14 days |
| Chumakov/CoviVac | Inactivated | 2-dose | 90.0% + although Phase III clinical trials aren’t expected to start until April 2021 | Safe | The broader immune response that is likely to protect against any variants, compared to the other vaccines developed in Russia |
| Pfizer/BioNTech (BNT162b2) | Protein Subunit | 2-dose | 95.0% | Safe | High neutralizing antibody titers, high antigen specific CD8+, and Th1 type CD4 + T-cell response |
| Moderna (mRNA-1273) | Protein Subunit | 2-dose | 94.1% | Safe | Activates T-cells to facilitate the production of antibody-producing B-cells; response is seen after 14 days |
| EpiVacCorona (Russia) | Protein Subunit | 2-dose | 82.1% | Safe | Induces virus-specific and neutralizing antibodies |
| ZF2001/Anhui Zhifei Longcom Bio | Protein Subunit | 3-dose | - | Safe, based on data populated from Phase I and II of the clinical trial | Full immunity still under investigation |
| Johnson and Johnson/Janssen (JNJ-78436735; Ad26.COV2. s) | Viral Vector | 1-dose | 66.3% | Safe | Well tolerated humoral response with the most protection 2 weeks post vaccine |
| Oxford/AstraZeneca (AZD1222) | Viral Vector | 2-dose | 63.09% | Safe | Well tolerated humoral response |
| Sputnik V/Gam-COVID-Vac (Russia) | Viral Vector | 2-dose | 91.6% | Safe | Well tolerated humoral response |
| Convidicea Ad5-nCoV/(CanSino) | Viral Vector | 1-dose | 65.7% | Safe | Well tolerated humoral response |